Apex Healthcare Bhd
KLSE:AHEALTH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (13), the stock would be worth MYR2.61 (0% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 13 | MYR2.61 |
0%
|
| 3-Year Average | 13 | MYR2.61 |
0%
|
| 5-Year Average | 13.7 | MYR2.75 |
+5%
|
| Industry Average | 9.1 | MYR1.84 |
-30%
|
| Country Average | 11.3 | MYR2.28 |
-13%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
MYR1.7B
|
/ |
Oct 2025
130.8m
|
= |
|
|
MYR1.7B
|
/ |
Dec 2025
93.8m
|
= |
|
|
MYR1.7B
|
/ |
Dec 2026
96.9m
|
= |
|
|
MYR1.7B
|
/ |
Dec 2027
109.1m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| MY |
A
|
Apex Healthcare Bhd
KLSE:AHEALTH
|
1.9B MYR | 13 | 28.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
867B USD | 28.4 | 42 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.4B USD | 16.9 | 26.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.9 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.8B GBP | 15.7 | 28.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.8B CHF | 12.2 | 19.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
283.6B USD | 9.7 | 15.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 7.9 | 10.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.6B USD | 7.5 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.8B USD | 7.2 | 16.8 |
Market Distribution
| Min | 0.5 |
| 30th Percentile | 7.2 |
| Median | 11.3 |
| 70th Percentile | 16.9 |
| Max | 56 436.5 |
Other Multiples
Apex Healthcare Bhd
Glance View
Apex Healthcare Bhd.is an investment holding company, which engages in the manufacture and trade of pharmaceutical and consumer healthcare products. The company is headquartered in Malacca, Melaka. The company went IPO on 2000-06-26. The firm operates through three segments: Manufacturing, Distribution, and Corporate. The Manufacturing segment is engaged in manufacturing and marketing of pharmaceutical products. The Distribution segment is engaged in wholesale, marketing, and distribution of pharmaceutical, consumer healthcare products and medical devices. The Corporate segment comprising investments, properties and others. The company develops manufacture and market XEPA branded off-patent generic pharmaceuticals and medical devices. The company also conducts contract manufacturing for pharmaceutical companies. The company provides specialist market access services for pharmaceutical companies through the provision of regulatory, redressing, sales, marketing and logistics services via a network of eight distribution facilities in Singapore and Malaysia. Its subsidiaries include Xepa-Soul Pattinson (Malaysia) Sdn. Bhd., Apex Pharmacy Marketing Sdn. Bhd. and ABio Marketing Sdn. Bhd.
